MYD88 L265P Mutation Is a Possible Unfavorable Prognostic Factor in Patients with Diffuse B-Cell Lymphoma

被引：2
|
作者：
Sidorova, Anna A. [1 ]
Zvonkov, Eugene E. [1 ]
Sudarikov, Andrey B. [1 ]
Severina, Nataliya A. [2 ]
Kovrigina, Alla M. [1 ]
Troitskaya, Vera V. [1 ]
Savchenko, Valeri G. [1 ]
机构：
[1] Natl Res Ctr Hematol, Moscow, Russia
[2] Natl Res Ctr Hematol, Mol Hematol, Moscow, Russia
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.5051.5051
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma
    Hamadeh, Fatima
    MacNamara, Stephen P.
    Aguilera, Nadine S.
    Swerdlow, Steven H.
    Cook, James R.
    MODERN PATHOLOGY, 2015, 28 (04) : 564 - 574
  • [42] Defining the Morphologic Spectrum of Extramedullary Lymphoplasmacytic Lymphoma with the MYD88 L265P Mutation
    Hamadeh, F.
    MacNamara, S.
    Swerdlow, S. H.
    Cook, J. R.
    LABORATORY INVESTIGATION, 2014, 94 : 350A - 350A
  • [43] Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation
    Carreno, Ester
    Clench, Tim
    Steeples, Laura R.
    Salvatore, Serena
    Lee, Richard W. J.
    Dick, Andrew D.
    Pawade, Joya
    ACTA OPHTHALMOLOGICA, 2019, 97 (01) : E138 - E139
  • [44] Defining the Morphologic Spectrum of Extramedullary Lymphoplasmacytic Lymphoma with the MYD88 L265P Mutation
    Hamadeh, F.
    MacNamara, S.
    Swerdlow, S. H.
    Cook, J. R.
    MODERN PATHOLOGY, 2014, 27 : 350A - 350A
  • [45] The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia
    Tadic, Ljiljana
    Marjanovic, Goran
    Macukanovic-Golubovic, Lana
    Krstic, Miljan
    Jevtovic-Stoimenov, Tatjana
    Kostov, Milos
    Smelcerovic, Zaklina
    Stojanovic, Mariola
    JOURNAL OF BUON, 2016, 21 (05): : 1259 - 1267
  • [46] Development of MyD88 L265P mutation-specific TCR gene therapy for treatment of B-cell lymphoma and leukemia.
    Cinar, Oezcan
    Busse, Antonia
    Pezzutto, Antonio
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 119 - 119
  • [47] Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
    Li, Wei
    Wang, Ruirui
    Wang, Junhao
    Chai, Dafei
    Xie, Xiaohui
    Young, Ken H.
    Cao, Ya
    Li, Yong
    Yu, Xinfang
    BLOOD, 2025, 145 (10) : 1047 - 1060
  • [48] Therapy for MYD88 L265P DLBCL
    Vermaat, Joost S. P.
    de Groen, Ruben A. L.
    BLOOD, 2025, 145 (10) : 998 - 1000
  • [49] MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Xu, Lian
    Yang, Guang
    Zhou, Yangsheng
    Liu, Xia
    Cao, Yang
    Sheehy, Patricia
    Manning, Robert J.
    Patterson, Christopher J.
    Tripsas, Christina
    Arcaini, Luca
    Pinkus, Geraldine S.
    Rodig, Scott J.
    Sohani, Aliyah R.
    Harris, Nancy Lee
    Laramie, Jason M.
    Skifter, Donald A.
    Lincoln, Stephen E.
    Hunter, Zachary R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09): : 826 - 833
  • [50] MYD88 L265P mutation in cutaneous involvement by Waldenstrom macroglobulinemia
    Alegria-Landa, Victoria
    Prieto-Torres, Lucia
    Santonja, Carlos
    Cordoba, Raul
    Manso, Rebeca
    Requena, Luis
    Rodriguez-Pinilla, Socorro M.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (07) : 625 - 631
12345